IRAK1 and neoplasm: Overall, the intracellular dysregulation of IL1/TLR/IRAK signaling within tumor cells or infiltrating immune cells in the tumor microenvironment may contribute to chronic inflammation-driven cancer survival, growth, invasion, immune evasion, and chemoresistance [124,125,126,127].